Treatment and outcomes of Candida osteomyelitis: Review of 53 cases from the PATH Alliance® registry

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 1, 2014, Pages 135-141

  Neofytos, D ^a   Huprikar, S ^b   Reboli, A ^c   Schuster, M ^d   Azie, N ^e   Franks, B ^e   Horn, D ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Rowan University ^*  (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f David Horn LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; DEBRIDEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOMYELITIS; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895064777     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1939-0     Document Type: Article

References (20)

1. Gamaletsou MN, Kontoyiannis DP, Sipsas NV, Moriyama B, Alexander E, Roilides E, Brause B, Walsh TJ (2012) Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis 55:1338-1351
2. Slenker AK, Keith SW, Horn DL (2012) Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis 73:89-93
3. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535
4. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30:696-709
5. Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O; Voriconazole/Bone Invasive Aspergillosis Study Group (2005) Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40:1141-1147
6. Kirby A, Hassan I, Burnie J (2006) Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect 52:405-414
7. Yang SC, Shao PL, Hsueh PR, Lin KH, Huang LM (2006) Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation. Acta Paediatr 95:629-630
8. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D (2012) The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 73:293-300
9. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, Pfaller MA, Weiss MA, Webster KM, Neofytos D (2007) Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 59:407-414
10. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
11. Horn D, Neofytos D, Fishman J, Steinbach W, Anaisie E, Marr KA, Pfaller M, Olyaei A (2007) Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis 26:907-914
12. [No authors listed] (1999) National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 27:520-532
13. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172-1177
14. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48:1695-1703
15. Miller LG, Hajjeh RA, Edwards JE Jr (2001) Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 32:1110
16. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM (2005) Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26:540-547
17. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses Study Group (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634-643
18. Rentz AM, Halpern MT, Bowden R (1998) The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27:781-788
19. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645
20. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232-1239